NASDAQ:JSPR Jasper Therapeutics (JSPR) Stock Price, News & Analysis $0.59 +0.02 (+3.28%) Closing price 04:00 PM EasternExtended Trading$0.57 -0.02 (-2.80%) As of 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Jasper Therapeutics Stock (NASDAQ:JSPR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Jasper Therapeutics alerts:Sign Up Key Stats Today's Range$0.54▼$0.5950-Day Range$0.57▼$0.8952-Week Range$0.32▼$2.69Volume634,167 shsAverage Volume855,990 shsMarket Capitalization$19.48 millionP/E RatioN/ADividend YieldN/APrice Target$7.33Consensus RatingHold Company Overview Jasper Therapeutics, Inc. is a clinical-stage biotechnology company developing antibody therapies for diseases driven by mast cells and for conditions requiring the controlled depletion of blood-forming stem cells. The company’s research is centered on targeting c-Kit, a receptor involved in the survival and development of mast cells and hematopoietic stem and progenitor cells. Jasper’s lead product candidate is briquilimab, formerly known as JSP191, an investigational monoclonal antibody designed to block c-Kit activity. The company has evaluated briquilimab in mast cell-mediated diseases, including chronic spontaneous urticaria, and in conditioning regimens intended to prepare patients for hematopoietic stem cell transplantation or certain gene therapies. These programs remain subject to clinical testing and regulatory review. Founded in 2019 and headquartered in Redwood City, California, Jasper Therapeutics serves the global biopharmaceutical and clinical research markets through its development programs. The company’s activities are focused primarily on advancing briquilimab and related therapies rather than selling commercial products.AI Generated. May Contain Errors. Read More Jasper Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreJSPR MarketRank™: Jasper Therapeutics scored higher than 34% of companies evaluated by MarketBeat, and ranked 663rd out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingHold Consensus RatingJasper Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on no strong buy ratings, 3 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialJasper Therapeutics has a consensus price target of $7.33, representing about 1,152.7% upside from its current price of $0.59.Amount of Analyst CoverageJasper Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Jasper Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Jasper Therapeutics are expected to grow in the coming year, from ($1.14) to ($0.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jasper Therapeutics is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Jasper Therapeutics is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJasper Therapeutics has a P/B Ratio of 3.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Jasper Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.16% of the float of Jasper Therapeutics has been sold short.Short Interest Ratio / Days to CoverJasper Therapeutics has a short interest ratio ("days to cover") of 16.43, which indicates bearish sentiment.Change versus previous monthShort interest in Jasper Therapeutics has recently increased by 5.76%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldJasper Therapeutics does not currently pay a dividend.Dividend GrowthJasper Therapeutics does not have a long track record of dividend growth. News and Social Media1.3 / 5News Sentiment0.02 News SentimentJasper Therapeutics has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Jasper Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for JSPR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Jasper Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Jasper Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders3.90% of the stock of Jasper Therapeutics is held by insiders.Percentage Held by Institutions79.85% of the stock of Jasper Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Jasper Therapeutics' insider trading history. Receive JSPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JSPR Stock News HeadlinesJasper Therapeutics (NASDAQ:JSPR) Cut to Sell at Wall Street ZenSeptember 19, 2026 | americanbankingnews.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Recommendation of "Moderate Buy" from BrokeragesSeptember 18, 2026 | americanbankingnews.comShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he says has never existed before. In a similar setup in the past, select investors saw $1,000 turn into over $1 million within a few years. Del Real just released a full video breakdown of what is driving this move and how to prepare.September 24 at 1:00 AM | Digest Publishing (Ad)Jasper Therapeutics Announces Key Regulatory and Clinical AppointmentsSeptember 15, 2026 | globenewswire.comJasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 9, 2026 | globenewswire.comJasper Therapeutics, Inc.: Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 15, 2026 | finanznachrichten.deJasper Therapeutics Reports Q2 2026 Results and Completion of Kira Pharmaceuticals AcquisitionAugust 14, 2026 | quiverquant.comQJasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 14, 2026 | globenewswire.comSee More Headlines JSPR Stock Analysis - Frequently Asked Questions How have JSPR shares performed this year? Jasper Therapeutics' stock was trading at $1.83 at the start of the year. Since then, JSPR stock has decreased by 68.0% and is now trading at $0.5854. How were Jasper Therapeutics' earnings last quarter? Jasper Therapeutics, Inc. (NASDAQ:JSPR) announced its quarterly earnings data on Friday, August, 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.17. When did Jasper Therapeutics' stock split? Shares of Jasper Therapeutics reverse split before market open on Thursday, January 4th 2024.The 1-10 reverse split was announced on Thursday, January 4th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 4th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Jasper Therapeutics? Shares of JSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Jasper Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Jasper Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V). Company Calendar Last Earnings8/14/2026Today9/24/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 JSPR's financial health is in the Green zone, according to TradeSmith. JSPR has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:JSPR CIK1788028 Webjaspertherapeutics.com Phone650-549-1400FaxN/AEmployees22Year FoundedN/APrice Target and Rating Average Price Target for Jasper Therapeutics$7.33 High Price Target$17.00 Low Price Target$2.00 Potential Upside/Downside+1,152.7%Consensus RatingHold Rating Score (0-4)2.29 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$75.80 million Net MarginsN/A Pretax MarginN/A Return on Equity-884.17% Return on Assets-143.83% Debt Debt-to-Equity RatioN/A Current Ratio1.48 Quick Ratio1.47 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book3.90Miscellaneous Outstanding Shares33,275,000Free Float31,977,000Market Cap$19.48 million OptionableOptionable Beta3.04 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:JSPR) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThey're shrinking your dollars every single monthSince 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...American Alternative | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredNASA's ISS Replacement Could Go to This Tiny Space FirmNASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to...Behind the Markets | SponsoredAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...Stansberry Research | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jasper Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
